% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Alig:305508,
      author       = {S. K. Alig$^*$ and A. Reinhardt$^*$ and B. von
                      Tresckow$^*$},
      title        = {{W}hat is established in the treatment of diffuse large
                      {B}-cell lymphoma? [{W}as ist gesichert in der {T}herapie
                      des diffusen großzelligen {B}-{Z}ell-{L}ymphoms?]},
      journal      = {Die Innere Medizin},
      volume       = {nn},
      issn         = {2731-7080},
      address      = {Berlin},
      publisher    = {Springer Medizin},
      reportid     = {DKFZ-2025-02192},
      pages        = {nn},
      year         = {2025},
      note         = {epub},
      abstract     = {Diffuse large B‑cell lymphoma (DLBCL) is the most common
                      aggressive non-Hodgkin lymphoma, with a median age at
                      diagnosis of 71 years, predominantly affecting older adults.
                      Risk factors include immunodeficiency, autoimmune disorders,
                      viral infections, and certain environmental exposures,
                      although most cases lack a clear predisposition. Diagnosis
                      is based on lymph node excision, histopathological and
                      molecular analysis, and positron emission
                      tomography-computed tomography (PET-CT) staging. First-line
                      standard therapy is R‑CHOP (rituximab, cyclophosphamide,
                      doxorubicin, vincristine, prednisone), de-escalated to four
                      cycles for young, low-risk patients (FLYER trial). For
                      patients with International Prognostic Index (IPI) ≥ 2,
                      the POLARIX trial showed superior progression-free survival
                      with polatuzumab vedotin-R-CHP (rituximab, cyclophosphamide,
                      doxorubicin, prednisone) over R‑CHOP. Older patients are
                      generally treated with dose-reduced R‑mini-CHOP or
                      alternatives. In relapsed/refractory disease, chimeric
                      antigen receptor (CAR) T‑cell therapy with axicabtagene
                      ciloleucel or lisocabtagene maraleucel has replaced
                      high-dose chemotherapy with autologous stem cell
                      transplantation for refractory or early relapses, including
                      transplant-ineligible patients. Additional antibody-based
                      therapies-such as polatuzumab-bendamustine-rituximab,
                      tafasitamab-lenalidomide, loncastuximab, and bispecific
                      antibodies (glofitamab, epcoritamab, odronextamab)-expand
                      treatment options, some achieving durable remissions.
                      Glofitamab plus gemcitabine-oxaliplatin is a new standard
                      for first relapse when CAR T‑cell therapy is not feasible
                      or as bridging before CAR T. Future directions include
                      earlier integration of immunotherapies, personalized
                      strategies guided by genetic subgroups, and broader use of
                      liquid biopsy for subtyping, minimal residual disease
                      detection, and treatment guidance.},
      subtyp        = {Review Article},
      keywords     = {Antibodies, bispecific (Other) / CAR T‑cell therapy
                      (Other) / CHOP protocol (Other) / Lymphoma, non-Hodgkin
                      (Other) / Rituximab (Other)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41125821},
      doi          = {10.1007/s00108-025-01999-x},
      url          = {https://inrepo02.dkfz.de/record/305508},
}